Search | TVST | ARVO Journals

Showing 1 – 20 of 41

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelicmutations in GUCY2D (LCA1)

Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):9.

ARVO Annual Meeting Abstract June 2024

Gene-edited monkey model of Usher 1B: Assessment of gene therapy

Martha Neuringer; Jonathan Stoddard; Rene Reynaga; Junghyun Ryu; Jon D Hennebold; Carol B Hanna; John V Brigande; Hannah Woolard; Andreas K Lauer; David Wilson; Mark E Pennesi; Sanford L Boye; Shannon Elizabeth Boye; Renee Christine Ryals; Trevor J Mcgill; Lauren Renner

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4269.

ARVO Annual Meeting Abstract June 2024

Using cytokine profiling to characterize the immune response associated with AAV subretinal administration

Rene Stephen Reynaga; Jonathan Stoddard; Lauren Renner; Hannah Woolard; Andreas K Lauer; Sanford L Boye; Shannon Elizabeth Boye; Steven Grey; Alison Weiss; Will Liguore; Trevor J Mcgill; Paul Yang; Renee Christine Ryals; Martha Neuringer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6088.

ARVO Annual Meeting Abstract June 2023

Modification of rAAV capsid to improve retinal vascular endothelial tropism

Ramesh Periasamy; Dwani Patel; Sanford L Boye; Shannon E Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):768.

ARVO Annual Meeting Abstract June 2023

Six-month safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1)

Christine Nichols Kay; Paul Yang; Artur V Cideciyan; Allen Ho; Andreas K Lauer; Shannon E Boye; Sanford L Boye; Alejandro J Roman; Vivian Wu; Alexandra V Garafalo; Alexander Sumaroka; Laura P Pardon; Dan Yoon; Kenji P Fujita; Samuel Jacobson

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1914.

Retina February 2023

Identifying and Overcoming Challenges in Developing Effective Treatments for Usher 1B: A Workshop Report

PDF

Shannon E. Boye; Todd Durham; Amy Laster; Claire M. Gelfman; José-Alain Sahel
TAGS: blindness, genes, genetics, myosin viia, natural history, outcome measures, pathology, research personnel, retina, vision
Trans. Vis. Sci. Tech.. 2023; 12(2):2. https://doi.org/10.1167/tvst.12.2.2

ARVO Annual Meeting Abstract June 2022

Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.

Ramesh Periasamy; Dwani D Patel; Sanford L Boye; Shannon E Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):66 – A0039.

ARVO Annual Meeting Abstract June 2022

Investigating the functional role of β4B-tubulin in vision

Urikhan Sanzhaeva; Shannon E. Boye; Visvanathan Ramamurthy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1932 – F0350.

ARVO Annual Meeting Abstract June 2021

Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP)

Andras M Komaromy; Christine Harman; Kristin Koehl; Amanda Anderson; Sanford L Boye; Juan Pedro Steibel; Leandro Teixeira; Carol B Toris; Sayoko E Moroi; Shannon E Boye

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2783.

ARVO Annual Meeting Abstract June 2021

Development of rAAV capsid mutant vectors with improved tropism for retinal vascular endothelial.

Ramesh Periasamy; Dwani Patel; Shannon E Boye; Sanford L Boye; Daniel M Lipinski

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1468.

ARVO Annual Meeting Abstract June 2021

Gene therapy and gene-editing approaches to treat vision loss in a murine model of Acadian Usher syndrome

Katelyn N Robillard; Bhagwat V Alapure; Sanford L Boye; Shannon E Boye; Nicolas G Bazan; Jennifer J Lentz

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1184.

ARVO Annual Meeting Abstract July 2019

Highly Efficient Foveal Cone Transduction by AAV44.9 and AAV2(4pMutΔHS) Mediated by Lateral Spread Following Extrafoveal Subretinal Injection

Ryan F. Boyd; Joshua T Bartoe; Thomas S Vihtelic; James J Peterson; Hangning Zhang; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1330.

ARVO Annual Meeting Abstract July 2019

Long-term stable intraocular pressure (IOP) control and optic nerve head (ONH) preservation following AAV-mediated ocular gene therapy in a canine model of ADAMTS10 -open-angle glaucoma (OAG)

Andras M Komaromy; Kristin L Koehl; Christine Harman; Sanford L Boye; Juan P. Steibel; Leandro B C Teixeira; Carol B Toris; Sayoko Eileen Moroi; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6470.

ARVO Annual Meeting Abstract July 2018

Investigating tolerability of subretinally delivered dual AAV-MYO7A vectors in non-human primate (NHP)

Kaitlyn Calabro; Sanford L Boye; Kevin Mccullough; Diego Fajardo; W Clay Smith; Christianne E Strang; Douglas C. Witherspoon; Dibyendu Chakraborty; Paul D Gamlin; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4535.

ARVO Annual Meeting Abstract July 2018

AAV 44.9- a novel capsid that efficiently transduces photoreceptors and retinal pigment epithelium

Shreyasi Choudhury; Russell Mellen; Kevin Mccullough; James Peterson; Diego Fajardo; John Chiorini; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4536.

ARVO Annual Meeting Abstract July 2018

Subfoveal Injections in Non-Human Primates: Safety and Efficacy Following Administration of a Photoreceptor-Targeted AAV5

Ryan F. Boyd; Joshua T. Bartoe; Thomas S Vihtelic; Sanford L Boye; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5662.

ARVO Annual Meeting Abstract July 2018

An AAV-CRISPR/Cas9 gene editing approach for GUCY2D -associated cone rod dystrophy (CORD6)

Kevin Mccullough; Sanford L Boye; Diego Fajardo; Christianne E Strang; Douglas C. Witherspoon; Sebastian Gloskowski; Abhishek Dass; Paul D Gamlin; Morgan Maeder; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):6020.

ARVO Annual Meeting Abstract July 2018

Development of a drug-regulated, broad-spectrum neuroprotective gene therapy for retinal degeneration

John D Ash; Casey Keuthan; Aisha Imam; Sanford L Boye; Shannon Elizabeth Boye; Clayton Santiago

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3961.

ARVO Annual Meeting Abstract June 2017

AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.

Kevin Tyler Mccullough; Laura Adamson-Small; James Peterson; Sanford Boye; Nathalie Clément; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4084.

ARVO Annual Meeting Abstract June 2017

Directed Evolution of Enhanced AAV Capsid Variants Following Intravitreal Injection in Macaque

Sanford L Boye; Shreyasi Choudhury; Damien Marsic; Christianne E Strang; John J Alexander; C. Douglas Witherspoon; Sergei Zolotukhin; Paul D Gamlin; Shannon Elizabeth Boye

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4087.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelicmutations in GUCY2D (LCA1)

Gene-edited monkey model of Usher 1B: Assessment of gene therapy

Using cytokine profiling to characterize the immune response associated with AAV subretinal administration

Modification of rAAV capsid to improve retinal vascular endothelial tropism

Six-month safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1)

Identifying and Overcoming Challenges in Developing Effective Treatments for Usher 1B: A Workshop Report

Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.

Investigating the functional role of β4B-tubulin in vision

Four-year follow up of intraocular pressure (IOP) control in a canine model of open-angle glaucoma (OAG) treated with adeno-associated virus (AAV)-mediated modification of gene expression within the aqueous humor outflow pathways (AHOP)

Development of rAAV capsid mutant vectors with improved tropism for retinal vascular endothelial.

Gene therapy and gene-editing approaches to treat vision loss in a murine model of Acadian Usher syndrome

Highly Efficient Foveal Cone Transduction by AAV44.9 and AAV2(4pMutΔHS) Mediated by Lateral Spread Following Extrafoveal Subretinal Injection

Long-term stable intraocular pressure (IOP) control and optic nerve head (ONH) preservation following AAV-mediated ocular gene therapy in a canine model of ADAMTS10 -open-angle glaucoma (OAG)

Investigating tolerability of subretinally delivered dual AAV-MYO7A vectors in non-human primate (NHP)

AAV 44.9- a novel capsid that efficiently transduces photoreceptors and retinal pigment epithelium

Subfoveal Injections in Non-Human Primates: Safety and Efficacy Following Administration of a Photoreceptor-Targeted AAV5

An AAV-CRISPR/Cas9 gene editing approach for GUCY2D -associated cone rod dystrophy (CORD6)

Development of a drug-regulated, broad-spectrum neuroprotective gene therapy for retinal degeneration

AAV5 made by rHSV complementation displays increased retinal transduction relative to AAV5 made by plasmid transfection.

Directed Evolution of Enhanced AAV Capsid Variants Following Intravitreal Injection in Macaque

To View More...

You must be signed into an individual account to use this feature.